Mycoleptodonoides aitchisonii suppresses asthma via Th2 and Th1 cell regulation in an ovalbumin-induced asthma mouse model

SOON-YOUNG LEE1*, CHUN-SIK BAE2*, JI-HYE SEO1, SEUNG SIK CHO3, MIN-SUK BAE4, DEUK-SIL OH5 and DAE-HUN PARK1

1College of Oriental Medicine, Dongshin University, Naju, Jeollanam-do 58245; 2College of Veterinary Medicine, Chonnam National University, Gwangju 61186; 3Department of Pharmacy, College of Pharmacy, Mokpo National University; 4Department of Environmental Engineering, College of Engineering, Mokpo National University, Muan, Jeollanam-do 58554; 5Jeollanam-do Wando Arboretum, Wando, Jeollanam-do 59105, Republic of Korea

Received March 2, 2016; Accepted February 7, 2017

DOI: 10.3892/mmr.2017.7901

Abstract. Asthma is a chronic respiratory disease related to hyper-responsiveness. The majority of patients suffer mild symptoms, however, some cases, especially in the young and the elderly, can lead to death by apnea. Mycoleptodonoides aitchisonii (M. aitchisonii) is an edible mushroom that has previously been reported to possess several bioactive properties, such as the synthesis of nerve growth factors, anti-obesity effects and the ability to prevent cell death. In the current study, the authors evaluated the anti-asthmatic effects of M. aitchisonii using an ovalbumin-induced asthma mouse model. M. aitchisonii dose-dependently suppressed the levels of white blood cells, eosinophils and immunoglobulin (Ig)E in BALB/c mice, resulting from ovalbumin-induced asthma. M. aitchisonii recovered the typical asthmatic morphological changes in lungs, such as mucous hyper-secretion, epithelial layer hyperplasia, eosinophil infiltration and various cell surface molecules, such as CD3, CD4, CD8, CD19 and major histocompatibility complex class II. With the exception of CD19+ cells and IL-12p40, M. aitchisonii affected almost all factors related to asthma induction including the T helper (Th)1/Th2 transcription factors, T-bet and GATA-3, Th1-related cytokines, Th2-related cytokines and proinflammatory cytokines. In addition, M. aitchisonii significantly inhibited the expression of IL-5, IL-13 and IL-6. The authors concluded that M. aitchisonii may be a promising drug candidate against asthma.

Introduction

Asthma is a severe respiratory disease classified as one of the hyper-responsive immune diseases. According to the 2013 report from the World Health Organization, asthma patients numbered ~235 million worldwide in 2013 (1). The United States Environmental Protection Agency (EPA) estimated in 2013 that there were 25.9 million asthma patients in the USA alone. In addition, the EPA stated that asthma was among the most serious respiratory diseases that leads to hospitalization, especially in children under 15 years of age (2). Various allergens can trigger asthma, such as dust mites, cockroaches, pet dander, viral infections, pollen, mold, fungi, tobacco smoke and pollutants (1). Asthma is an incurable disease that is related to the pulmonary system, and presents itself with various symptoms ranging from coughing to constructive apnea, all resulting from mucous secretion, goblet cell hyperplasia, epithelial cell shedding, basement membrane thickening and eosinophil infiltration (3,4).

Asthma may be induced by an imbalance of T helper (Th)1 and Th2 cells, as well as various other factors related to disease occurrence. The transcription factor, T-bet, serves a role as a Th1 cell transcription factor (5,6), producing Th1-related cytokines including interferon (IFN)-γ, which is stimulated by T-bet to produce more T-bet in a positive feedback loop. Interleukin (IL)-12 is a key cytokine that regulates the balance between Th1 and Th2 cells (7). It consists of a p35 subunit expressed ubiquitously and a p40 subunit that is restricted to IL-12-producing cells (8). IL-12 stimulates Th1-related immunoglobulins, including IgG2a, and it influences Th cell trafficking (9).

GATA-3 is a Th2 cell transcription factor (10). In a manner similar to T-bet, GATA-3 regulates Th2-related cytokines and accelerates the differentiation of Th2-related cytokines, including IL-4. Following IL-4 differentiation by GATA-3, IL-4 stimulates the production of more GATA-3 in a positive feedback loop. IL-5 increases the eosinophil population (11). IL-13 and IL-4 enhance B cell activation and Ig E production (12). IL-6 is a proinflammatory cytokine (13) and, because it is a regulatory factor for CD4+ cell balance (14), IL-6 is an important factor in asthma regulation. TNF-α is
a proinflammatory cytokine induced by mast cells that has several regulatory functions that are related to asthma, such as smooth muscle contraction (15), neutrophil and eosinophil attractions (16) and T cell activation, which involves cytokine release (17).

Symptomatic relievers have been investigated in the past as asthma is a hyper-responsive disease and is difficult to completely eradicate/cure (18). For several decades, steroids were commonly prescribed for asthma, but the drugs have many severe adverse effects such as inhibiting the growth of children (19,20), cataracts and glaucoma, hypertension, hyperlipidemia, peptic ulcers, myopathy and immunological suppression (21). Consequently, there have been many efforts to find more effective candidates from natural products with fewer adverse effects (22,23). M. atichisonii is a mushroom that has been consumed for a long time in East Asia (24) and has been reported to have several medicinal effects, such as the synthesis of nerve growth factors (25), anti-obesity (26) and the prevention of cell death (27).

In the present study, the authors attempted to identify anti-asthmatic drug candidates from natural products to reduce the adverse effects of existing therapies, and to develop a drug that is more effective against asthma. Using immunohistochemical studies, M. atichisonii was determined to reduce the physiological and histopathological changes related to asthma in the bronchoalveolar lavage fluid (BALF), including the number of white blood cells, differential cell count and immunoglobulin (Ig)E in the lungs, as well as the associated morphological changes and asthma-inducing factors.

Materials and methods

*Mycoleptodonoides* (M.) *atichisonii* preparation. *M. atichisonii* used in the present study was provided by the Jeollanam-do Wando Arboretum (Wando, Korea). The fresh fruiting bodies were hot air-dried and ground into a powder. *M. atichisonii* extract was prepared by boiling 1 kg of mycelium powder in 10 l filtered sterile water for 8 h at 50°C. The supernatant was saved and the pellet was re-boiled with 10 l water for 8 h. Insoluble material was removed by filtration and a two-fold volume of cold ethanol was added to the filtrate to precipitate the polysaccharide. Following standing for 8 h with the following primary antibodies (diluted 1:100 to 1:200): rabbit anti-mouse CD19 polyclonal (cat no. 250585; BioLegend, San Diego, CA, USA), rat anti-mouse CD8 monoclonal (cat no. 14-9766; eBioscience, Inc., San Diego, CA, USA), rabbit anti-mouse CD3 monoclonal (cat no. 555248; BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer’s protocol (n=8 per group).

**Histopathological analysis.** Lung tissue was fixed in 10% (v/v) formaldehyde solution for 10 days at room temperature, dehydrated in a graded ethanol series (99.9, 90, 80 and 70%), and embedded in paraffin. Paraffin-embedded lung tissue was then sectioned (4 µm) longitudinally and stained with hematoxylin and eosin. In addition, the sections were stained with Periodic Acid-Schiff (PAS; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 1 mg aluminum hydroxide hydrate (Prod #77176; Thermo Fisher Scientific, Inc. Waltham, MA, USA) in 500 µl saline. From days 21 to 25, all mice, except for those used as control, were challenged once daily with 5% OVA for 30 min using a nebulizer (3 ml/min, NE-U17; Omron Corporation, Kyoto, Japan). During the same 5 day period, the treatment groups were also administered once daily with oral doses of sterilized tap water, DEX, 10, 100 or 1,000 mg/kg/day *M. atichisonii* 1 h prior to the OVA challenge.

**Ethics statement.** All experiments were approved by the Institutional Animal Care and Use Committee at Dongshin University (Naju, Korea; approval no. 2014-08-04).

**BALF analysis.** A total of one day following the final treatment, the mice were anesthetized with intraperitoneal injections of 50 mg/kg Zoletil (Virbac, Carros, France), and their tracheas were cannulated with disposable animal feeding needles. Lavages were performed with three 0.4 ml aliquots of cold phosphate-buffered saline (PBS; cat no. 17-316F; Lonza, Walkersville, MD, USA). BALF samples were collected and immediately centrifuged at 900 x g for 5 min at room temperature (Sorvall Legend Micro 17R; Thermo Fisher Scientific, Inc.). The cell pellets were resuspended in PBS for total and differential cell counts. The numbers of total and differential cells were counted using the Hemavet Multispecies Hematology system (n=8 per group; Drew Scientific Inc., Miami Lakes, FL, USA). Levels of IgE in the BALF were measured using a specific mouse IgE enzyme-linked immunosorbent assay kit (cat no. 555248; BD Biosciences, Franklin Lakes, NJ, USA), according to the manufacturer's protocol (n=8 per group).

**Immunohistochemical analysis.** Deparaffinized tissue sections were treated with 3% hydrogen peroxide in methanol for 10 min to remove endogenous peroxidase. Antigen retrieval was carried out with sodium citrate buffer (0.1 M) using a microwave. The slides were incubated with normal serum to block non-specific binding and then incubated overnight at 4°C with the following primary antibodies (diluted 1:100 to 1:200); Rabbit anti-mouse CD3 polyclonal (cat no. ab5690; 1:100; Abcam, Cambridge, MA, USA), rat anti-mouse CD4 monoclonal (cat no. 14-9766; 1:200; eBioscience, Inc., San Diego, CA, USA), rat anti-mouse CD8 monoclonal (cat no. sc-18913; 1:100; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), rabbit anti-mouse CD19 polyclonal (cat no. 250585; 1:100; Abbiotec, San Diego, CA, USA), rat anti-mouse MHC class II monoclonal (cat no. sc-59318; 1:100; Santa Cruz Biotechnology, Inc.), rabbit anti-mouse Tbx21/T-bet...
polyclonal (cat no. bs-3599R; 1:100; BIOSS, Beijing, China), goat anti-mouse GATA-3 (cat no. TA305795; 1:100; OriGene Technologies, Inc., Rockville, MD, USA), rat anti-mouse IFN-γ monoclonal (cat no. sc-74104; 1:100), rat anti-mouse IL-12p35 monoclonal (cat no. sc-9350; 1:100), rat anti-mouse IL-12p40 monoclonal (cat no. sc-57258; 1:100) (all from Santa Cruz Biotechnology, Inc.), rabbit anti-mouse TNF-α polyclonal (cat no. 3053R-100; 1:200; BioVision Milpitas, CA, USA), rat anti-mouse IL-4 monoclonal (cat no. sc-73318; 1:100), rabbit anti-mouse IL-5 polyclonal (cat no. sc-7887; 1:100), goat anti-mouse IL-6 polyclonal (cat no. sc-1265; 1:100), and goat anti-mouse IL-13 polyclonal (cat no. sc-1776; 1:100) (all from Santa Cruz Biotechnology, Inc.). The slides were incubated for 10 min with a biotinylated secondary antibody (cat no. PK-7800; Vector Laboratories, Inc., Burlingame, CA, USA) and horseradish-peroxidase conjugated streptavidin. Signals were detected using a 3,3-diaminobenzidine tetrahydrochloride substrate chromogen solution (cat no. SK-4105; Vector Laboratories), and cells were counterstained with Mayer’s hematoxylin. To determine the number of positively stained cells, five random, non-overlapping fields of view were selected, and cells were counted (magnification, x200) from three separately immunostained lung sections per animal (n=8 per group).

Gas chromatography/mass spectrometry (GC-MS) analysis. GC-MS (Agilent 5975C MSD and 7890A GC; Agilent Technologies, Inc., Santa Clara, CA, USA) was tuned by perfluorotribuylamine (cat no. 442747; Sigma-Aldrich; Merck KGaA) using three mass fragments (m/z) of 69.0, 219.0 and 502.0 in the condition of electron ionization. A 5MS GC column (DB-5 cross-linked 5%phenylmethyl silicone; Agilent Technologies, Inc.) was used for the analysis as this column has low bleed that improves sensitivity for constituent identification. The GC oven was heated using the following program: Isothermal at 65°C for 10 min and increasing by 10°C every min to 300°C with He as the carrier gas. The summarized operation parameters for the GC-MS are presented in Table I. In order to analyze the quality of extract in M. aitchisonii, the certain amount of dried samples by dehydration procedure was prepared. The samples were extracted using 10 min sonication at room temperature, twice with dichloromethane, followed by sonication twice with acetone using a sonicator (Branson® CPXH; Branson Ultrasonics Corporation, Dallas, TX, USA). The composited extract was evaporated by high volume nitrogen blowdown (TurboVap II; Caliper Life Sciences, Hopkinton, MA, USA) to reach 5-10 ml and was further evaporated to a final volume of 100 µl using low volume nitrogen blowdown (MGS-2200; Tokyo Rikakikai Co., Ltd., Tokyo, Japan). A final extract volume of 100 µl was sialylated with N,O-bis(trimethylsilyl) trifluoroacetamide (Supelco; Sigma-Aldrich; Merck KGaA) to derivatize the constituents to their trimethylsilyl-derivatives (TMS-derivatives) prior to GC-MS analysis.

Statistical analysis. Data are presented as the mean ± standard deviation. Group differences were evaluated by one-way analysis of variance followed by Dunnett’s multiple comparison tests. Statistical significance was set at P<0.05 or P<0.01.

Results

M. aitchisonii dose-dependently suppressed the populations of WBCs and eosinophils in BALF. In the OVA-induced asthma...
group, *M. atichisonii* dramatically increased WBC count, when compared with the level of WBCs in the control group. However, in the DEX treated group, WBC number decreased by a similar amount in the control group (Fig. 1A; P<0.05 or P<0.01). *M. atichisonii* suppressed WBC proliferation induced by OVA in a dose-dependent manner. The number of WBCs in the 1,000 mg/kg *M. atichisonii* treatment group was similar to that in the DEX treatment.

Eosinophil number was dramatically more affected by *M. atichisonii* treatment than WBC number (Fig. 1B; P<0.05 or P<0.01). *M. atichisonii* dose-dependently suppressed eosinophil proliferation and the levels of eosinophils in the 1,000 mg/kg/day *M. atichisonii* treatment group, and this was similar to that in DEX treatment.

*M. atichisonii* effectively decreased the quantity of IgE in the BALF of OVA-induced asthma mice. IgE is related to the hyperresponsiveness of asthma and serves an important role in asthma occurrence (28). *M. atichisonii* effectively decreased the level of IgE in a dose-dependent manner, which was increased by OVA treatment, when compared with that in OVA treatment group (8.2±0.69 ng/ml). In addition, the quantity of IgE in the 1,000 mg/kg treatment group (2.7±1.02 ng/ml) was similar to that in the DEX treatment group (2.4±0.54 ng/ml; Fig. 2; P<0.05 or P<0.01).

*M. atichisonii* recovered the typical asthmatic morphological changes in the lung. To analyze the morphological changes in the lung that were induced by OVA treatment, hematoxylin and eosin staining was used, in
addition to PAS staining (Fig. 3). In the lungs of mice with OVA-induced asthma, typical histopathological changes were observed such as airway remodeling, mucous hyper-secretion, epithelial hyperplasia and eosinophil infiltration (Fig. 3A-b). In particular, PAS stained mucous hyper-secretion in the bronchioles was clearly observed using the specific staining method (Fig. 3B-b). DEX, which is typically used as a representative anti-asthmatic drug, significantly suppressed the morphological changes in the lung (Fig. 3A-c) and completely prevented mucous secretion (Fig. 3B-c). *M. atichisonii* not only recovered the asthmatic alterations (Fig. 3A-d-f) but also suppressed mucous secretion (Fig. 3B-d-f). These results suggested that *M. atichisonii* may ameliorate airway obstruction.

*M. atichisonii* downregulated the expressions of MHC class II molecules and T cells. In the 100 mg/kg/day *M. atichisonii* treatment and 1,000 mg/kg/day *M. atichisonii* treatment, expression of CD3+ total T cell (Fig. 4A; P<0.05 or P<0.01) was almost fully diminished. The expression of CD4+ helper T cells was suppressed in a dose-dependent manner (Fig. 4B; P<0.05 or P<0.01). A total of 1,000 mg/kg/day *M. atichisonii* treatment effectively inhibited the expression of CD4+ helper T cells (Fig. 4B-f; P<0.05 or P<0.01) when compared with the DEX treatment group (Fig. 4B-c; P<0.05 or P<0.01). In the 100 mg/kg/day or more *M. atichisonii* treatment group, the expression pattern of CD8+ cytotoxic T cells (Fig. 4C; P<0.05 or P<0.01) was the same as that observed for the CD4+ helper T cells, which was that they were almost fully diminished. Although *M. atichisonii* downregulated the expression of CD19+ B cells, the decreased level of CD19+ B cells was lower compared with other groups including CD3+ total T cell, CD4+ helper T cell, and CD8+ cytotoxic T cell (Fig. 4D; P<0.05 or P<0.01). The expression of MHC class II+ molecule (Fig. 4E; P<0.05 or P<0.01) almost disappeared in the 100 mg/kg/day *M. atichisonii* treatment and in the 1,000 mg/kg/day *M. atichisonii* treatment groups. The 1,000 mg/kg/day *M. atichisonii* treatment effectively inhibited the expression of MHC class II+ molecules (Fig. 4E-f; P<0.05 or P<0.01) more, when compared with the DEX treatment group (Fig. 4E-c; P<0.05 or P<0.01).

Although *M. atichisonii* appears to control levels of both T cells (CD3+, CD4+, CD8+) and B cells (CD19+), the potency to modulate B cell (CD19+) proliferation may be smaller than that of T cell (CD3+, CD4+, CD8+) proliferation, however it downregulated CD3+ positive cells (total T cell) and CD8+ positive cells (cytotoxic T cell) and dose-dependently regulated CD4+ positive cell (helper T cell).

*M. atichisonii* controlled T-bet and GATA-3. In order to compare the suppressive effects of the Th1 cell transcription
factor, T-bet, and the Th2 cell transcription factor, GATA-3, the changes of expressions on T-bet and GATA-3 were measured via immunohistochemical staining (Fig. 5). The expressions of T-bet and GATA-3 in the OVA treatment...
A. In Figure 5 treatment suppressed the expression of IFN-γ, however, the effect of \textit{M. atichisonii} is smaller than the effect of DEX. (B) Although \textit{M. atichisonii} inhibited the expression of IL-12p35, the effect of \textit{M. atichisonii} in 10 mg/kg treatment and 100 mg/kg treatment groups was small. The 1,000 mg/kg \textit{M. atichisonii} treatment suppressed the expression of IL-12p35 similarly to DEX treatment. (C) IL-12p40 may be affected by DEX and \textit{M. atichisonii} as the changes of expression level were not large following treatment. (D) Quantification of expression. Each bar represents the mean ± standard deviation (n=6). a, Con; b, OVA; c, DEX; d, 10 mg/kg/day \textit{M. atichisonii}; e, 100 mg/kg/day \textit{M. atichisonii}; f, 1,000 mg/kg/day \textit{M. atichisonii}. *P<0.05 vs. Con; **P<0.01 vs. Con; ***P<0.05 vs. OVA-induced asthma. $^*$P<0.001 vs. OVA-induced asthma. $^{**}$P<0.001 vs. DEX treatment. $^{***}$P<0.01 vs. DEX treatment. Br, bronchiole; V, vessel; IFN-γ, interferon-γ; IL, interleukin; Con, control; OVA, ovalbumin; DEX, dexamethasone.

\textit{M. atichisonii} suppressed the expression of Th1-related cytokines. \textit{M. atichisonii} dose-dependently downregulated the expression of T-bet and GATA-3, which was induced by OVA, to a similar level as the control groups (Fig. 5A and B). Although \textit{M. atichisonii} dose-dependently downregulated the expression of T-bet, there was no significant difference between 100 mg/kg \textit{M. atichisonii} treatment and 1,000 mg/kg \textit{M. atichisonii} treatment (Fig. 5C; P<0.05 or P<0.01). Conversely, from treatment with 10 mg/kg \textit{M. atichisonii} to 1,000 mg/kg, the changes in GATA-3 expression were dependent on the dose-response relationship (Fig. 5C; P<0.05 or P<0.01).

\textit{M. atichisonii} almost fully inhibited the expression of Th2-related cytokines such as IL-5, IL-6, and IL-13. In order to measure the downregulation effect of \textit{M. atichisonii} on Th2-related cytokines, such as TNF-α (Fig. 7A), IL-4 (Fig. 7B), IL-5 (Fig. 7C), IL-6 (Fig. 7D) and IL-13 (Fig 7E), immunoassay was conducted. Although \textit{M. atichisonii} did not completely prevent the expression of TNF-α, it was similar to that of DEX (Fig. 7A). \textit{M. atichisonii} dose-dependently suppressed the expression of IL-4, but the suppression was less than DEX (Fig. 7B and F). The expression of IL-5 was controlled by \textit{M. atichisonii} and the effect was similar to DEX. In particular, IL-6 and IL-13 were dose-dependently suppressed by \textit{M. atichisonii} treatment more than by DEX (Fig. 7F).

Nicotinic acid (niacin), oleic acid and linoleic acid may act as anti-asthmatic compounds in \textit{M. atichisonii}. To identify the compounds in \textit{M. atichisonii} that may possess anti-asthmatic properties, GC-MS analysis was conducted. Not all compounds in \textit{M. atichisonii} were isolated, however nicotinic acid (niacin), oleic acid and linoleic acid were identified as candidate compounds. Fig. 8 presents the identification of silylated fatty acids. Of the identified fatty acids, niacin, linoleic acid and linoleic acid were analyzed at retention times of 18.21, 28.01 and 28.06 min respectively.

**Discussion**

Eosinophils are a key mediator of innate and adaptive immunity (29,30). The differentiation and activation of eosinophils is strongly related to the IL-5 gene; if the IL-5 gene is depleted, airway eosinophilia cannot occur (31). Eosinophils are increased in number in asthma, and this is induced by IL-5 (11). In allergic situations, eosinophils remain for 8-12 h in circulating blood, and for an additional 8-12 days in tissue following the removal of the stimuli (32). In the present study, although the expression of IL-5 was more suppressed by \textit{M. atichisonii}
Figure 7. *M. aitchisonii* significantly inhibited the expression of Th2-related cytokines in a dose-dependent manner. (A) *M. aitchisonii* suppressed the expression of TNF-α similarly to dexamethasone treatment. (B) *M. aitchisonii* downregulated the expression of IL-4. (C) *M. aitchisonii* significantly inhibited the expression of IL-5, similar to treatment with dexamethasone. (D) *M. aitchisonii* dramatically inhibited the expression of IL-6 more than treatment with dexamethasone. (E) The expression of IL-13 dramatically inhibited the expression of IL-6 more than treatment with dexamethasone. (F) Quantification of expression. Each bar represents the mean ± standard deviation (n=6). a, Con; b, OVA; c, DEX; d, 10 mg/kg/day *M. aitchisonii*; e, 100 mg/kg/day *M. aitchisonii*; f, 1,000 mg/kg/day *M. aitchisonii*. *P*<0.05 vs. control; **P*<0.001 vs. control; *P*<0.05 vs. OVA-induced asthma; **P*<0.001 vs. OVA-induced asthma; *P*<0.05 vs. DEX treatment, **P*<0.01 vs. DEX treatment. Th, T helper; TNF-α, tumor necrosis factor-α; IL, interleukin; Br, bronchiole; V, vessel; Con, control; OVA, ovalbumin; DEX, dexamethasone.

Figure 8. Gas chromatography/mass spectrometry analysis of *M. aitchisonii*.
than that of eosinophils, the downregulatory patterns were similar for both, indicating that *M. atichisonii* may suppress eosinophils through IL-5. As the level of IL-5 suppression by *M. atichisonii* was larger than the other effects, IL-5 might be one of the key mediators in the preventive mechanism of *M. atichisonii* against asthma.

MHC class II molecules, which are made by antigen presenting cells, have the function of presenting processed antigens to helper T cells and triggering acquired immunity (33). MHC class II+ expression was almost completely eliminated by 100 mg/kg *M. atichisonii* treatment, confirming that *M. atichisonii* may completely control MHC class II molecule expression, which serves an important role in asthma occurrence.

Based on the changes in IFN-γ levels, a controversial hypothesis regarding the mechanism underlying asthma was previously proposed that implicated the Th1/Th2 cell imbalance and T cell priming induced by allergens (34). *M. atichisonii* slightly decreased not only the expressions of Th2-related factors, but also that of IFN-γ increased by OVA (Fig. 4D) in the present study and this result may support the T cell priming theory. IL-12 is produced by cells including dendritic cells, macrophages and monocytes (35) and is considered an IFN-γ-inducing factor because it stimulates the production of IgM and IFN-γ (8). Although *M. atichisonii* suppresses or inhibits most asthma-induced factors, the key factors for the anti-asthmatic effect may be IL-5, IL-6 and IL-13 (Fig 7C-E). The ratio of Th17 cells and Treg cells is related to the late phase asthma induction and, in the case of late phase asthma, the analysis of Th17 cells and Treg cells may be important (36).

In the current study, the authors determined that *M. atichisonii* lowered the OVA-induced level of WBCs and eosinophils in BALF and the level of IgE in serum, recovered respiratory changes, such as mucous secretion, epithelial cell hyperplasia and eosinophil infiltration and finally ameliorated airway obstruction. This was controlled by T cell-related molecules, such as CD3+, CD4+ and CD8+, as well as by MHC class II+ molecules that were increased following OVA treatment. Ultimately, this led to downregulated T-βet and GATA-3 levels, and a dose-dependent decreased to the level of Th1-related cytokines, IFN-γ and IL-12p40, and Th2-related cytokines, TNF-α, IL-4, IL-5, IL-6 and IL-13. In particular, the expression of IL-5, IL-6 and IL-13 increased by OVA treatment were almost completely eliminated by *M. atichisonii* application.

In this study, niacin, oleic acid and linoleic acid in *M. atichisonii* were identified and isolated. Melton (37) previously reported that nicotinic acid reduced the frequency of asthmatic paroxysm. In addition, oleic acid has beneficial effects in inflammatory related diseases (38) and linoleic acid is one of the mediators that regulate inflammations and asthma (39).

The present study is one of the ongoing efforts to identify appropriate anti-asthmatic drug candidates. From the results, it may be concluded that *M. atichisonii* has an anti-asthmatic effect and that the pharmacological effect may be based on the suppression or inhibition of various factors related to Th1 and Th2. In particular, IL-5, IL-6 and IL-13 may be some of the most important factors related to asthma occurrence, and they are modulated by *M. atichisonii*. *M. atichisonii* is a promising drug that is believed to be key in the control of asthma.

Acknowledgements

The current study was conducted with a fund from the Korea Forest Service (grant no. S121313L090100).

References

1. World Health Organization: Asthma Fact Sheet No 307, November, 2013.
2. United States Environmental Protection Agency (EPA): Asthma Facts EPA-402-F-04-019, March, 2013.
3. Kay AB: Allergy and allergic diseases. First of two parts. N Engl J Med 344: 30-37, 2001.
4. National Asthma Education and Prevention Program: National asthma education and prevention program. Expert panel report: Guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol 110 (5 Suppl): S14-S219, 2002.
5. Luxarres V and Glümcher LH: T-bet in disease. Nature Immunol 12: 597-606, 2011.
6. Zhu J, Jankovic D, Oler AJ, Wei G, Sharma S, Hu G, Guo L, Yagi R, Yamane H, Punksody G, et al: The transcription factor T-bet is induced by multiple pathways and prevents an endogenous T helper-2 program during T helper-1 responses. Immunity 37: 660-673, 2012.
7. Zedan MM, El-Chennawi FA and Fouda AE: Interleukin-12 and peripheral blood invariant natural killer T cells as an axis in childhood asthma pathogenesis. Iran J Allergy Asthma Immunol 9: 43-48, 2010.
8. Trinchieri G: Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol 70: 83-243, 1998.
9. Hamza T, Barnett JB and Li B: Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11: 789-806, 2010.
10. Yagi R, Zhu J and Paul WE: An updated view on transcription factor GATA3-33 mediated regulation of Th1 and Th2 cell differentiation. Int Immunol 23: 415-420, 2011.
11. Uhlm TG, Kim BS and Chung YI: Eosinophil development, regulation of eosinophil-specific genes and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res 4: 68-79, 2012.
12. Platts-Mills TA: The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 164: S1-S5, 2001.
13. Kamimura D, Ishihara K and Hirano T: IL-6 signal transduction and its physiological roles: The signal orchestration model. Rev Physiol Biochem Pharmacol 149: 1-38, 2003.
14. Neveu WA, Allard JL, Raymond DM, Bourassa LM, Burns SM, Bunn JY, Irvin CG, Kaminsky DA and Kincon M: Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Respir Res 11: 28, 2010.
15. Berry M, Brightling C, Pavord I and Wardlaw A: TNF-alpha in asthma. Curr Opin Pharmacol 7: 279-282, 2007.
16. Lukacs NW, Shieter RM, Chensue SW, Widmer M and Kunkel SL: TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol 154: 5411-5417, 1995.
17. Scheurich P, Thoma B, Ucer Y and Pfizenmaier K: Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138: 1768-1790, 1987.
18. Bosnjak B, Stelzmueller B, Erb KJ and Epstein MM: Treatment of allergic asthma: Modulation of Th2 cells and their responses. Respir Res 12: 114, 2011.
19. Barnes PJ: Current issues for establishing inhaled corticosteroids as the anti-inflammatory agents of choice in asthma. J Allergy Clin Immunol 101: S427-S433, 1998.
20. Wise J: Corticosteroids for asthma may suppress growth in children in first year of treatment, researchers say. BMJ 349: g4623, 2014.
21. Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F and Russo E: Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother 4 (Suppl 1): S94-S98, 2013.

22. Seo JW, Cho SC, Park SJ, Lee EJ, Lee JH, Han SS, Pyo BS, Park DH and Kim BH: 1'-Acetoxycchavicol acetate isolated from Alpinia galangal ameliorates ovalbumin-induced asthma in mice. PLoS One 8: e56447, 2013.

23. Bang MA, Seo JH, Seo JW, Jo GH, Jung SK, Yu R, Park DH and Park SJ: Bacillus subtilis KCTC 11782BP-produced alginate oligosaccharide effectively suppresses asthma via T-helper cell type 2-related cytokines. PLoS One 10: e0117524, 2015.

24. Chandrasekaran G, Oh DS and Shin HJ: Versatile applications of the culinary-medicinal mushroom Mycoceptodonoides atchisonii (Berk) Maas G. (Higher Basidiomycetes): A review. Int J Med Mushrooms 14: 395–401, 2012.

25. Okuyama S, Lam NV, Hatakeyama T, Terashima T, Yamagata K and Yokogoshi H: Mycoceptodonoides atchisonii affects brain nerve growth factor concentration in newborn rats. Nutr Neurosci 7: 341-349, 2004.

26. Lee MR, Begum S, Oh DS, Wee AJ, Yun BS and Sung CK: Ameliorating effect of Mycoceptodonoides atchisonii on high-fat diet-induced obese mice. Prev Nutr Food Sci 19: 69-74, 2014.

27. Choi JH, Suzuki T, Okumura H, Noguchi K, Kondo M, Nagai K, Hiraiz H and Kawagishi H: Endoplasmic reticulum stress suppressive compounds from the edible mushroom Mycoceptodonoides atchisonii. J Nat Prod 77: 1729-1733, 2014.

28. Burrows B, Martinez FD, Halonen M, Barbee RA and Cline MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320: 271-277, 1989.

29. Shamri R, Xenakis JJ and Spencer LA: Eosinophils in innate immunity: An evolving story. Cell Tissue Res 343: 57-83, 2011.

30. Galioto AM, Hess JA, Nolan TJ, Schad GA, Lee JJ and Abraham D: Role of eosinophils and neutrophils in innate and adaptive protective immunity to larval Strongyloides stercoralis in mice. Infect Immun 74: 5730-5738, 2006.

31. Kouro T and Takatsu K: IL-5- and eosinophil-mediated inflammation: From discovery to therapy. Int Immunol 21: 1303-1309, 2009.

32. Young B, Lowe JS, Stevens A, et al: Wheater's functional histology: a text and colour atlas. 5th edition. Edinburg, Elsevier, 2006.

33. Holling TM, Schooten E and van Den Elsen PJ: Function and regulation of MHC class II molecules in T-lymphocytes: Of mice and men. Human Immunol 65: 282-290, 2004.

34. Kim YK: Th1/Th2 imbalance vs. T cell priming in asthma. BioWave 7: SubNo.1, 2005.

35. Airoldi I, Guglielmino R, Carra G, Corcione A, Gerosa F, Taborelli G, Trinchieri G and Pistoia V: The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes. Haematologica 87: 434-442, 2002.

36. Singh A, Yamamoto M, Ruan J, Choi JY, Gauvreau GM, Olek S, Hoffmueller U, Carlsten C, FitzGerald JM, Boulet LP, et al: Th17/Treg ratio derived using DNA methylation analysis is associated with the late phase asthmatic response. Allergy Asthma Clin Immunol 10: 32, 2014.

37. Melton G: Treatment of Asthma by Nicotinic Acid. Br Med J I: 600-601, 1943.

38. Carrillo C, Cavia Mdel M and Alonso-Torre S: Role of oleic acid in immune system; mechanism of action; a review. Nutr Hosp 27: 978-990, 2012.

39. Wendell SG, Baffi C and Holguin F: Fatty acids, inflammation, and asthma. J Allergy Clin Immunol 133: 1255-1264, 2014.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.